Joichi Heianna

Dr. Joichi Heianna

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HTHayato Tomita
Hayato Tomita
TYTsuneo Yamashiro
Tsuneo Yamashiro
JHJoichi Heianna
Joichi Heianna
TNToshiyuki Nkasone
Toshiyuki Nkasone
TKTatsuaki Kobayashi
Tatsuaki Kobayashi
YKYasuyuki Kobayashi
Yasuyuki Kobayashi
We investigated the value of deep learning (DL) in differentiating between benign and metastatic cervical lymph nodes (LNs) using pretreatment contrast-enhanced computed tomography (CT). This retrospective study analyzed 86 metastatic and 234 benign (non-metastatic) cervical LNs at levels I–V in 39 patients with oral squamous cell carcinoma (OSCC) who underwent preoperative CT and neck dissection. LNs were randomly divided into training (70%), validation (10%), and test (20%) sets. For the validation and test sets, cervical LNs at levels I–II were evaluated. Convolutional neural network analysis was performed using Xception architecture. Two radiologists evaluated the possibility of metastasis to cervical LNs using a 4-point scale. The area under the curve of the DL model and the radiologists’ assessments were calculated and compared at levels I–II, I, and II. In the test set, the area under the curves at levels I–II (0.898) and II (0.967) were significantly higher than those of each reader (both, p < 0.05). DL analysis of pretreatment contrast-enhanced CT can help classify cervical LNs in patients with OSCC with better diagnostic performance than radiologists’ assessments alone. DL may be a valuable diagnostic tool for differentiating between benign and metastatic cervical LNs.

1 March 2021 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JHJoichi Heianna
Joichi Heianna
WMWataru Makino
Wataru Makino
MTMasafumi Toguchi
Masafumi Toguchi
TITomotaka Iraha
Tomotaka Iraha
KIKazuki Ishikawa
Kazuki Ishikawa
SMSadayuki Murayama
Sadayuki Murayama

10 October 2021 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
JHJoichi Heianna
Joichi Heianna
WMWataru Makino
Wataru Makino
HHHitoshi Hirakawa
Hitoshi Hirakawa
SAShinya Agena
Shinya Agena
HTHayato Tomita
Hayato Tomita
SMSadayuki Murayama
Sadayuki Murayama

24 December 2021 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
PDF file
JHJoichi Heianna
Joichi Heianna
WMW. Makino
W. Makino
HHH. Hirakawa
H. Hirakawa
YYY. Yamashita
Y. Yamashita
HTH. Tomita
H. Tomita
SMS. Murayama
S. Murayama

14 November 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
JHJoichi Heianna
Joichi Heianna
WMWataru Makino
Wataru Makino
TATakuro Ariga
Takuro Ariga
KIKazuki Ishikawa
Kazuki Ishikawa
TKTakeaki Kusada
Takeaki Kusada
SMSadayuki Murayama
Sadayuki Murayama

1 August 2017 in British Journal of Radiology
Verified
Journal Article
Open access
YKYoshino Kinjyo
Yoshino Kinjyo
YNYutaka Nagai
Yutaka Nagai
TTTakafumi Toita
Takafumi Toita
WKWataru Kudaka
Wataru Kudaka
TATakuro Ariga
Takuro Ariga
YAYoichi Aoki
Yoichi Aoki
Objective:To compare patients with cervical cancer who were primarily treated with concurrent chemoradiotherapy (CCRT) using 20 mg m−2 CDDP for 5 days every 3 weeks with weekly regimens of 40 mg m−2.Methods:We retrospectively analyzed 185 patients with Stage IB–IVA squamous-cell carcinoma of the cervix who were treated with CCRT between 2005 and 2013 at our hospital. The CCRT regimen consisted of cisplatin (CDDP) at 20 mg m−2 for 5 days every 3 weeks or 40 mg m−2 weekly, administered concomitantly with RT.Results:The median age was 50 years (range: 22–70 years) in the triweekly group and was 50.5 years (range: 28–70 years) in the weekly group. The 5-year overall survival rate in the triweekly and weekly groups were 82.0% and 83.3%, respectively (p = 0.851); their disease-free survival rate was 79.6% and 78.1%, respectively (p = 0.672). In the triweekly group, 56 patients (50.9%) had grade 3/4 leukopenia, which was significantly higher than that of 11 patients (15%) in the weekly group (p < 0.0001).Conclus...